Levodopa (administration & dosage) < Levodopa (adverse effects) < Levodopa (antagonists & inhibitors)

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 123.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000010 (1999)	F. Durif [France] ; M. Vidailhet ; B. Debilly ; Yves Agid [France]	Worsening of levodopa-induced dyskinesias by motor and mental tasks.
000013 (1998)		Ropinirole: new preparation. Wait for more convincing data.
000027 (1999)	P. Krack [France] ; P. Pollak ; P. Limousin ; A. Benazzouz ; G. Deuschl ; A L Benabid	From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
000036 (1999)	O. Rascol [France] ; C. Brefel-Courbon ; S. Descombes ; J L Montastruc	Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
000037 (1999)	P. Damier [France]	New aspects in the pathophysiology of dyskinesia. Salpêtrière Deep Brain Stimulation Group.
000061 (1999)	M. Vidailhet [France] ; A M Bonnet ; R. Marconi ; F. Durif ; Yves Agid [France]	The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
000062 (1999)	O. Rascol [France]	L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
000080 (1999)	Yves Agid [France] ; E. Ahlskog ; A. Albanese ; D. Calne ; T. Chase ; J. De Yebenes ; S. Factor ; S. Fahn ; O. Gershanik ; C. Goetz ; W. Koller ; M. Kurth ; A. Lang ; A. Lees ; P. Lewitt ; D. Marsden ; E. Melamed ; P P Michel ; Y. Mizuno ; J. Obeso ; W. Oertel ; W. Olanow ; Werner Poewe [Autriche] ; P. Pollak ; E. Tolosa	Levodopa in the treatment of Parkinson's disease: a consensus meeting.
000081 (1999)	C. Dentresangle [France] ; L. Veyre ; D. Le Bars ; C. Pierre ; F. Lavenne ; P. Pollak ; J. Guerin ; J C Froment ; E. Brousolle	Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
000098 (2000)	P. Damier [France] ; L. Tremblay ; J. Féger ; E C Hirsch	[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
000102 (2000)	B P Bejjani [France] ; D. Dormont ; B. Pidoux ; J. Yelnik ; P. Damier ; I. Arnulf ; A M Bonnet ; C. Marsault ; Yves Agid [France] ; J. Philippon ; P. Cornu	Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance.
000103 (2000)	E C Hirsch [France]	Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
000104 (2000)	A L Benabid [France] ; A. Benazzouz ; P. Limousin ; A. Koudsie ; P. Krack ; B. Piallat ; P. Pollak	Dyskinesias and the subthalamic nucleus.
000106 (2000)	J L Houeto [France] ; P. Damier ; P B Bejjani ; C. Staedler ; A M Bonnet ; I. Arnulf ; B. Pidoux ; D. Dormont ; P. Cornu ; Yves Agid [France]	Subthalamic stimulation in Parkinson disease: a multidisciplinary approach.
000112 (2000)	B P Bejjani [France] ; I. Arnulf ; S. Demeret ; P. Damier ; A M Bonnet ; J L Houeto ; Yves Agid [France]	Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
000116 (2000)	O. Rascol [France] ; D J Brooks ; A D Korczyn ; P P De Deyn ; C E Clarke ; A E Lang	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
000132 (2000)	J J Ferreira [France] ; O. Rascol	Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
000137 (2000)	O. Rascol [France]	The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
000158 (2000)	V. Fraix [France] ; P. Pollak ; N. Van Blercom ; J. Xie ; P. Krack ; A. Koudsie ; A L Benabid	Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.
000174 (2001)	F. Durif [France] ; I. Devaux ; J J Pere ; J C Delumeau ; I. Bourdeix	Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
000197 (2001)	F. Maurel [France] ; H. Lilliu ; C. Le Pen	[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Levodopa (adverse effects)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Levodopa (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Levodopa (adverse effects)
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024